Literature DB >> 15979236

PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells.

Nomelí P Núñez1, Huaitian Liu, Gary G Meadows.   

Abstract

The PPAR-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone, and the PPAR-alpha ligand, WY-14643, were examined for their effects on proliferation and apoptosis of A375 melanoma, DU145 and PC3 prostate cancer, and MB-MDA-231 breast cancer. While 15-deoxy-Delta(12,14)-prostaglandin J(2) inhibited proliferation of A375 melanoma, ciglitazone was inactive against this and the other cell lines. Restriction of specific amino acids known to inhibit proliferation and induce apoptosis sensitized all cell lines to ciglitazone, and the combined effects were greater than the individual effects of either treatment. WY-14643 alone or in combination with amino acid deprivation was inactive. Normal fibroblasts were resistant to the treatments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979236     DOI: 10.1016/j.canlet.2005.05.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy.

Authors:  Anne R Diers; Brian P Dranka; Karina C Ricart; Joo Yeun Oh; Michelle S Johnson; Fen Zhou; Manuel A Pallero; Thomas M Bodenstine; Joanne E Murphy-Ullrich; Danny R Welch; Aimee Landar
Journal:  Biochem J       Date:  2010-08-15       Impact factor: 3.857

2.  Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Authors:  Ronac Mamtani; Kevin Haynes; Warren B Bilker; David J Vaughn; Brian L Strom; Karen Glanz; James D Lewis
Journal:  J Natl Cancer Inst       Date:  2012-08-09       Impact factor: 13.506

3.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

Review 4.  The complexities of obesity and diabetes with the development and progression of pancreatic cancer.

Authors:  Bin Bao; Zhiwei Wang; Yiwei Li; Dejuan Kong; Shadan Ali; Sanjeev Banerjee; Aamir Ahmad; Fazlul H Sarkar
Journal:  Biochim Biophys Acta       Date:  2010-12-01

5.  Herpesvirus-associated ubiquitin-specific protease (HAUSP) modulates peroxisome proliferator-activated receptor γ (PPARγ) stability through its deubiquitinating activity.

Authors:  Kyeong Won Lee; Jin Gu Cho; Chul Min Kim; A Young Kang; Min Kim; Byung Yong Ahn; Sung Soo Chung; Key-Hwan Lim; Kwang-Hyun Baek; Jong-Hyuk Sung; Kyong Soo Park; Sang Gyu Park
Journal:  J Biol Chem       Date:  2013-09-26       Impact factor: 5.157

6.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

7.  A gene expression signature of invasive potential in metastatic melanoma cells.

Authors:  Aaron R Jeffs; Amy C Glover; Lynn J Slobbe; Li Wang; Shujie He; Jody A Hazlett; Anshul Awasthi; Adele G Woolley; Elaine S Marshall; Wayne R Joseph; Cristin G Print; Bruce C Baguley; Michael R Eccles
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

8.  Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.

Authors:  Joshua P Klopper; Vibha Sharma; Andrew Berenz; William R Hays; Michele Loi; Umarani Pugazhenthi; Sherif Said; Bryan R Haugen
Journal:  Mol Cancer       Date:  2009-03-06       Impact factor: 27.401

9.  Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.

Authors:  Jennifer C Carter; Frank C Church
Journal:  PPAR Res       Date:  2009-08-06       Impact factor: 4.964

10.  New target genes for the peroxisome proliferator-activated receptor-γ (PPARγ) antitumour activity: Perspectives from the insulin receptor.

Authors:  Daniela P Foti; Francesco Paonessa; Eusebio Chiefari; Antonio Brunetti
Journal:  PPAR Res       Date:  2009-06-29       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.